We’ve sliced and diced our portfolio into distinct “trends” that define our edge.
We are pleased to report that as of April 2021 the SOSV Climate Tech 100 have raised $1.85 billion from investors and have a market cap of $5.65 billion. The average company is four years old. SOSV (our parent fund) has invested $89 million in these companies and was in most cases the first investor, though we continued investing through early rounds.
IndieBio has never been one to shy away from the riskiest and most impactful investments for our planet. In fact, we embrace them.
Boosting female representation in the startup world is an ongoing challenge, but we’re dedicated to gender balance, not only because it’s the right thing to do, but because we would be dismissing impressive companies otherwise. We’ve found that more gender balance leads to better workplace culture and better ideas being exchanged.
Future of Food
It’s not just that we can make meat and fish in the lab, or with mushrooms and chickpeas. It’s not just that AI can predict the best plant ingredients to make the best tasting milk and yogurt. And it’s not just that yeast can be fermented to produce the healthier and better food preservatives. We’re diving deep every day into the foods that will satisfy novelty-seekers and conventionalists alike.
We’re putting big bets on the newest technologies and trends we think are ahead of the curve.
Future of Medicine
Medicine ain’t what it used to be. Today, bloodletting, skull-drilling and giving children cocaine for toothaches are relics of the past. Tomorrow, so too will addictive opioids, chemotherapy, and psychiatric drugs that are non-selectively bathing our bodies in chemicals.
The future of medicine is an exciting one, and we’re excited to share the most exciting technologies that enable the next wave of medicine and healthcare.
Our mission has always been Human and Planetary Health from the beginning, so it’s hard to say which of our companies are “impact” companies (in some ways, they all are).
Here, we narrowed down the startups that are directly addressing sustainability issues, improving public health, mitigating inequality, and democratizing access to infrastructure and technologies.
Every season of the year, a new batch and about one-sixth of our alumni are in raise mode. These companies are currently raising and would love to talk to interested investors. We can set up those meetings or you can contact the companies directly.
In order to supply our agriculture and industries with an available source of nitrogen, we rely on a chemical process that requires 400˚C of heat and more pressure than at the bottom of the world’s deepest lake. It’s no wonder that ammonia production releases 500 million tons of CO2 annually (3% of the world’s carbon […]
Concrete is the third largest greenhouse gas emitter but even less known is how much sand is required to make it. Sand mining is responsible for ecosystem collapse through erosion, water outflows, and biodiversity loss. The shortage of sand has prompted researchers to replace it with more sustainable aggregates, but the previously unsolvable issue is […]
Founded by one of Turkey’s most famous young fashion designers, Gozen Bioworks is a biomaterials company that has created the world’s strongest and softest bio-based animal-free leather to date. Their latest product (Xylozen™) is twice as strong as animal leather, impossibly thin, and soft enough to replace lambskin in luxury tiers. The breakthrough in their […]
Reducing our vulnerability to disruptions in our supply of critical metals is important for national security, but the current methods used to mine and extract metals are too toxic, too energy intensive, and damage communities and the environment around the world. MetalX Biocycle is using synthetic biology to extract, concentrate, and purify rare earth metals […]
Industry leading companies like Impossible, Perfect Day (RebelBio), and EVERY (IndieBio) have shown the powerful commercial appeal of animal-free proteins. Behind this first wave comes a second wave: glycoproteins. Glycoproteins require precise glycosylations to accurately fold, recognize, and bind – driving functional performance needed in the food industry. To unlock this second wave of animal-free […]
To reach the full potential of RNA therapeutics, we have to understand how the tuning of just 4 ingredients in the delivery vehicle (lipid nanoparticles) can confer transfection and targeting efficiency. Dandelion is the first to leverage machine learning and biophysics in a systematic attempt to make sense of the chaos between LNP structure and […]
The past couple years, investors have heard that what plant based meats are missing is the fat. Solve the fat, solve the texture, so the logic goes. But real meat texture comes from the way that fats, proteins, and water are bound together (a burger is 75% water, after all). Ingrediome makes this possible with […]
Many incurable health problems are characterized by the death of cells that cannot regenerate or repair themselves upon damage or injury. Cell therapy employs stem cells to produce functional cells transplanted into patients to treat and potentially reverse the damage. The access to cell therapies has been limited by the manufacturing challenges for allogeneic transplants […]
Single-cell genomics has continued to undergo enormous progress since its inception more than a decade ago. Named twice as Method of the Year by the journal Nature, it continues to evolve with this innovation delivered by ArgenTAG. ArgenTAG has developed the first truly scalable single-cell solution for long-read sequencers. The company has fundamentally changed the […]
There has been a steady rise in Attention-deficit/hyperactivity disorder (ADHD) patients during the last 20 years with adult diagnosis doubling in the last decade. With up to a 91% heritability, and the fact that ADHD can be brought on by environmental factors, this isn’t a problem that’s going to go away… it’s only going to […]